Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.61 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27676916 | 1.00 | L3MBTL1 (0.61) | L3MBTL1ESR1ESR2FFAR2HTT | |
| SCHEMBL11859297 | 0.86 | L3MBTL1 (0.58) | L3MBTL1ESR1ESR2FFAR2SLC6A2 | |
| SCHEMBL192706 | 0.86 | L3MBTL1 (0.61) | L3MBTL1ESR1ESR2FFAR2SLC6A2 | |
| SCHEMBL4517176 | 0.86 | L3MBTL1 (0.49) | L3MBTL1FFAR2HTTMAPK1MAPT | |
| SCHEMBL17838862 | 0.84 | L3MBTL1 (0.60) | L3MBTL1ESR1ESR2MAPTMEN1 | |
| SCHEMBL1476384 | 0.84 | L3MBTL1 (0.57) | L3MBTL1ESR1ESR2MEN1KMT2A | |
| SCHEMBL7716645 | 0.84 | ESR1 (0.70) | L3MBTL1ESR1ESR2MAPTLMNA | |
| SCHEMBL3520738 | 0.83 | ESR1 (0.73) | L3MBTL1ESR1ESR2FFAR2MEN1 | |
| Hydrochloric Acid SCHEMBL191106 | 0.83 | L3MBTL1 (0.58) | L3MBTL1ESR1ESR2MAPTMEN1 | |
| SCHEMBL7718835 | 0.83 | ESR1 (0.55) | L3MBTL1ESR1ESR2HTTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002514161-A | — | — | 2002-05-14 | — | — | JP | claimed |
| EP-0927033-A1 | RETINOYLOXY(SUBSTITUTED)ALKYLENE BUTYRATES USEFUL FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | BAR-ILAN UNIVERSITY (IL) | 1999-07-07 | — | — | EP | claimed |
| EP-0927033-A4 | — | — | 1999-07-07 | — | — | EP | claimed |
| WO-1998000127-A1 | RETINOYLOXY(SUBSTITUTED)ALKYLENE BUTYRATES USEFUL FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | BAR-ILAN UNIVERSITY (IL) | 1998-01-08 | — | — | WO | claimed |
| US-10155770-B2 | Substituted pyrazolopyrimidines and method of use | ABBVIE INC. (US) | 2018-12-18 | — | — | US | disclosed |
| US-20180105530-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND METHOD OF USE | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-04-19 | — | — | US | disclosed |
| EP-3286192-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND METHOD OF USE | AbbVie Deutschland GmbH & Co KG (DE) | 2018-02-28 | — | — | EP | disclosed |
| US-9828381-B2 | Substituted pyrazolopyrimidines and method of use | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-11-28 | — | — | US | disclosed |
| WO-2016169995-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND METHOD OF USE | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-10-27 | — | — | WO | disclosed |
| US-20160304527-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND METHOD OF USE | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-10-20 | — | — | US | disclosed |
| EP-0927033-A1 | RETINOYLOXY(SUBSTITUTED)ALKYLENE BUTYRATES USEFUL FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | BAR-ILAN UNIVERSITY (IL) | 1999-07-07 | — | — | EP | disclosed |
| EP-0927033-A4 | — | — | 1999-07-07 | — | — | EP | disclosed |
| WO-1998000127-A1 | RETINOYLOXY(SUBSTITUTED)ALKYLENE BUTYRATES USEFUL FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | BAR-ILAN UNIVERSITY (IL) | 1998-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304527-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND METHOD OF USE | GABBR1, GABBR2, GABRB1 | L3MBTL1 2022/4885ESR1 1606/4885ESR2 1011/4885 |
| US-10155770-B2 | Substituted pyrazolopyrimidines and method of use | GABBR1, GABBR2, GABRB1 | L3MBTL1 2022/4885ESR1 1606/4885ESR2 1011/4885 |
| US-20180105530-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND METHOD OF USE | GABBR1, GABBR2, GABRB1 | L3MBTL1 2022/4885ESR1 1606/4885ESR2 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.